1. Articles in category: Immune Therapy

    1-24 of 327 1 2 3 4 ... 12 13 14 »
    1. Targeted drug distribution in tumor extracellular fluid of GD2-expressing neuroblastoma patient-derived xenografts using SN-38-loaded nanoparticles conjugated to the monoclonal antibody 3F8.

      Targeted drug distribution in tumor extracellular fluid of GD2-expressing neuroblastoma patient-derived xenografts using SN-38-loaded nanoparticles conjugated to the monoclonal antibody 3F8.

      J Control Release. 2017 Apr 12;:

      Authors: Monterrubio C, Paco S, Olaciregui NG, Pascual-Pasto G, Vila-Ubach M, Cuadrado-Vilanova M, Mar Ferrandiz M, Castillo-Ecija H, Glisoni R, Kuplennik N, Jungbluth A, de Torres C, Lavarino C, Cheung NV, Mora J, Sosnik A, Carcaboso AM

      Read Full Article
    2. Armed Oncolytic Adenovirus-Expressing PD-L1 Mini-Body Enhances Antitumor Effects of Chimeric Antigen Receptor T Cells in Solid Tumors

      Chimeric antigen receptor–modified T cells (CAR T cells) produce proinflammatory cytokines that increase expression of T-cell checkpoint signals such as PD-L1, which may inhibit their functionality against solid tumors. In this study, we evaluated in human tumor xenograft models the proinflammatory properties of an oncolytic adenovirus (Onc.Ad) with a helper-dependent Ad (HDAd) that expresses a PD-L1 blocking mini-antibody (mini-body; HDPDL1) as a strategy to enhance CAR T-cell killing.

      Read Full Article
      Mentions: Antibody PD-1
    3. Modulation of interactions of neuroblastoma cell lines with extracellular matrix proteins affects their sensitivity to treatment with the anti-GD2 ganglioside antibody 14G2a.

      Modulation of interactions of neuroblastoma cell lines with extracellular matrix proteins affects their sensitivity to treatment with the anti-GD2 ganglioside antibody 14G2a.

      Int J Oncol. 2017 Apr 07;:

      Authors: Horwacik I, Rokita H

      Abstract Children diagnosed with high risk neuroblastoma have poor prognosis which stimulates efforts to broaden therapies of the neoplasm. GD2-ganglioside (GD2) marks neuroblastoma cells and is a target for monoclonal antibodies.

      Read Full Article
      Mentions: Antibody Treatment
    4. Dinutuximab for maintenance therapy in pediatric neuroblastoma.

      Dinutuximab for maintenance therapy in pediatric neuroblastoma.

      Am J Health Syst Pharm. 2017 Apr 15;74(8):563-567

      Authors: McGinty L, Kolesar J

      Abstract PURPOSE: The pharmacology, clinical efficacy, safety, dosage and administration, and role in therapy of dinutuximab for the treatment of high-risk pediatric neuroblastoma are reviewed.

      Read Full Article
      Mentions: Treatment
    5. Orphan designation: Iodine (131I) murine IgG1 monoclonal antibody against CD276, for the: Treatment of neuroblastoma

      Review of designation Orphan designation On 27 February 2017, orphan designation (EU/3/17/1839) was granted by the European Commission to Y-mAbs Therapeutics A/S, Denmark, for iodine ( 131 I) murine IgG1 monoclonal antibody against CD276 (also known as 131 I-mu8H9) for the treatment of neuroblastoma. What is neuroblastoma? Neuroblastoma is a cancer of certain nerve cells which is usually seen as a lump in the abdomen or around the spine.

      Read Full Article
      Mentions: Antibody Treatment
    6. Biomarker May Identify Neuroblastoma Patients Most Likely to Benefit from Immunotherapy

      Biomarker May Identify Neuroblastoma Patients Most Likely to Benefit from Immunotherapy

      ​WASHINGTON — Among patients with high-risk neuroblastoma, those who had a certain combination of genotypes gained substantial benefit from adding immunotherapy to isotretinoin treatment, while it is uncertain whether those who lacked the combination gained benefit from immunotherapy, according to results from a randomized phase III clinical trial presented here at the AACR Annual Meeting 2017, April 1-5.

      Read Full Article
    7. Avoidance of On-Target Off-Tumor Activation Using a Co-stimulation-Only Chimeric Antigen Receptor.

      Avoidance of On-Target Off-Tumor Activation Using a Co-stimulation-Only Chimeric Antigen Receptor.

      Mol Ther. 2017 Mar 21;:

      Authors: Fisher J, Abramowski P, Wisidagamage Don ND, Flutter B, Capsomidis A, Cheung GW, Gustafsson K, Anderson J

      Abstract Chimeric antigen receptors (CARs) combine T cell activation with antibody-mediated tumor antigen specificity, bypassing the need for T cell receptor (TCR) ligation.

      Read Full Article
      Mentions: Antibody
    8. HLA-E inhibitor enhances the killing of neuroblastoma stem cells by co-cultured dendritic cells and cytokine-induced killer cells loaded with membrane-based microparticles.

      HLA-E inhibitor enhances the killing of neuroblastoma stem cells by co-cultured dendritic cells and cytokine-induced killer cells loaded with membrane-based microparticles.

      Am J Cancer Res. 2017;7(2):334-345

      Authors: Zhen Z, Yang K, Ye L, You Z, Chen R, Liu Y, He Y

      Read Full Article
    9. Bronchiectasis following treatment for high-risk neuroblastoma: A case series.

      Bronchiectasis following treatment for high-risk neuroblastoma: A case series.

      Pediatr Blood Cancer. 2017 Mar 10;:

      Authors: Adams M, Traunecker H, Doull I, Cox R

      Abstract High-risk (HR) neuroblastoma remains a very challenging disease to treat and long-term cure is only possible with intensive, multimodal treatment including chemotherapy, high-dose therapy, radiotherapy, surgery, and immunotherapy. As a result, treatment-related morbidity and late effects are common in survivors.

      Read Full Article
    10. Bronchiectasis following treatment for high-risk neuroblastoma: A case series

      High-risk (HR) neuroblastoma remains a very challenging disease to treat and long-term cure is only possible with intensive, multimodal treatment including chemotherapy, high-dose therapy, radiotherapy, surgery, and immunotherapy. As a result, treatment-related morbidity and late effects are common in survivors. This report outlines a case series of six patients who developed a chronic productive cough following treatment for HR neuroblastoma.

      Read Full Article
    11. Intrinsic Resistance of Solid Tumors to Immune Checkpoint Blockade Therapy

      Immune checkpoint blockade therapy (ICBT), which blocks negative immune-activating signals and maintains the antitumor response, has elicited a remarkable clinical response in certain cancer patients. However, intrinsic resistance (i.e., insensitivity of the tumors to therapy) remains a daunting challenge. The efficacy of ICBT is tightly modulated by the function of each step in the antitumor immunity cycle. Mechanistically, the number of mutations determines tumor immunogenicity.

      Read Full Article
    12. Vaccination targeting native receptors to enhance the function and proliferation of chimeric antigen receptor (CAR)-modified T cells.

      Vaccination targeting native receptors to enhance the function and proliferation of chimeric antigen receptor (CAR)-modified T cells.

      Clin Cancer Res. 2017 Feb 09;:

      Authors: Tanaka M, Tashiro H, Omer B, Lapteva N, Ando J, Ngo M, Mehta B, Dotti G, Kinchington PR, Leen AM, Rossig C, Rooney CM

      Read Full Article
    13. Aurora A kinase inhibition enhances oncolytic herpes virotherapy through cytotoxic synergy and innate cellular immune modulation.

      Aurora A kinase inhibition enhances oncolytic herpes virotherapy through cytotoxic synergy and innate cellular immune modulation.

      Oncotarget. 2017 Jan 28;:

      Authors: Currier MA, Sprague L, Rizvi TA, Nartker B, Chen CY, Wang PY, Hutzen BJ, Franczek MR, Patel AV, Chaney KE, Streby KA, Ecsedy JA, Conner J, Ratner N, Cripe TP

      Read Full Article
    14. GD2-Targeted Immunotherapy and Potential Value of Circulating microRNAs in Neuroblastoma.

      GD2-Targeted Immunotherapy and Potential Value of Circulating microRNAs in Neuroblastoma.

      J Cell Physiol. 2017 Feb 01;:

      Authors: Gholamin S, Miezaei H, Razavi SM, Hassanian SM, Saadatpour L, Masoudifar A, ShahidSales S, Avan A

      Abstract Neuroblastoma (NB) with various clinical presentation is a known childhood malignancy.

      Read Full Article
      Mentions: Immunotherapy
    15. T Cells Redirected to a Minor Histocompatibility Antigen Instruct Intratumoral TNF{alpha} Expression and Empower Adoptive Cell Therapy for Solid Tumors

      Donor-derived allogeneic T cells evoke potent graft versus tumor (GVT) effects likely due to the simultaneous recognition of tumor-specific and host-restricted minor histocompatibility (H) antigens. Here we investigated whether such effects could be reproduced in autologous settings by TCR gene–engineered lymphocytes.

      Read Full Article
    16. Respiratory Difficulties in Children With Underlying Asthma During Immunotherapy for High-risk Neuroblastoma.

      Respiratory Difficulties in Children With Underlying Asthma During Immunotherapy for High-risk Neuroblastoma.

      J Pediatr Hematol Oncol. 2017 Jan 24;:

      Authors: Metrock LK, Qayed M, Simon D, Cash T, O'Connor MG, Johnson S, Esiashvili N, Katzenstein HM

      Abstract Treatment of high-risk neuroblastoma now includes antibody based antitumor immunotherapy as part of standard care.

      Read Full Article
    17. Combination of bevacizumab, irinotecan, and temozolomide for refractory or relapsed neuroblastoma: Results of a phase II study

      The rationale for studying the combination of bevacizumab, irinotecan, and temozolomide (BIT) in neuroblastoma (NB) is based on the following: (i) vascular endothelial growth factor (VEGF) expression is associated with an aggressive phenotype, (ii) anti-VEGF antibody bevacizumab enhances irinotecan-mediated suppression of NB xenografts, (iii) bevacizumab safety has been established in pediatric phase I studies, and (iv) irinotecan + temozolomide (IT) is a standard salvage chemotherapy.

      Read Full Article
    18. The Role of Nursing Professionals in the Management of Patients With High-Risk Neuroblastoma Receiving Dinutuximab Therapy.

      The Role of Nursing Professionals in the Management of Patients With High-Risk Neuroblastoma Receiving Dinutuximab Therapy.

      J Pediatr Oncol Nurs. 2017 Jan 01;:1043454216680595

      Authors: Secola R, Marachelian A, Cohn SL, Toy B, Neville K, Granger M, Brentlinger A, Martin G

      Read Full Article
    19. Neuroblastoma patients with high-affinity FCGR2A, -3A and stimulatory KIR 2DS2 treated by long-term infusion of anti-GD2 antibody ch14.18/CHO show higher ADCC levels and improved event-free survival.

      Neuroblastoma patients with high-affinity FCGR2A, -3A and stimulatory KIR 2DS2 treated by long-term infusion of anti-GD2 antibody ch14.18/CHO show higher ADCC levels and improved event-free survival.

      Oncoimmunology. 2016;5(11):e1235108

      Authors: Siebert N, Jensen C, Troschke-Meurer S, Zumpe M, Jüttner M, Ehlert K, Kietz S, Müller I, Lode HN

      Read Full Article
      Mentions: Antibody
    20. Dynamic Changes, Regulatory Rewiring Occur as T Cells Respond to Infection

      "Researchers from Children’s Hospital of Philadelphia (CHOP) and the University of Iowa used sophisticated sequencing and computational techniques to investigate the molecular mechanisms during each stage of the CD8+ T cells’ responses. By identifying novel biological pathways and publishing details of these interactions, the study team aims to help uncover useful targets in developing better vaccines and cancer treatments."

      Read Full Article
    21. TGFβR1 Blockade with Galunisertib (LY2157299) Enhances Anti-Neuroblastoma Activity of Anti-GD2 Antibody Dinutuximab (ch14.18) with Natural Killer Cells.

      "Neuroblastomas express TGFB1 and TGFBR1 mRNA. Galunisertib suppressed SMAD activation in neuroblastoma cells induced by exogenous TGFβ1 or by patient blood and bone marrow plasma, and suppressed SMAD2 phosphorylation in human neuroblastoma cells growing in NSG mice. In NK cells treated in vitro with exogenous TGFβ1, galunisertib suppressed SMAD2 phosphorylation and restored the expression of DNAM-1, NKp30, and NKG2D cytotoxicity receptors, TRAIL death ligand, the release of perforin and granzyme A, and the direct cytotoxicity and ADCC of aNK cells against NB cells. Addition of galunisertib to adoptive cell therapy with aNK cells plus dinutuximab reduced tumor growth ...

      Read Full Article
    1-24 of 327 1 2 3 4 ... 12 13 14 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Popular Articles

  3. Researches in the News

    1. (5 articles) Antibody
    2. (2 articles) Immunotherapy
    3. (1 articles) Nanoparticles
    4. (1 articles) PD-1
  4. General Informations in the News

    1. (5 articles) Treatment